National Vision Holdings, Inc.
EYEDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
EYE Earnings Report
EPS Est: $0.09 | FQ end 2026-06 | Call: 2026-08-12 15:00:00
How EYE's past catalysts played out
Inactivated SARS-CoV-2 Vaccine (Vero cell)
COVID-19
Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Whooping Cough
SARS-CoV-2 Vaccine (Vero Cell), Inactivated
COVID-19 Pneumonia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Inactivated SARS-CoV-2 Vaccine (Vero cell) | Phase 3 | COVID-19 | - | - |
Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed | Phase 3 | Whooping Cough | - | - |
SARS-CoV-2 Vaccine (Vero Cell), Inactivated | Phase 3 | COVID-19 Pneumonia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in National Vision Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in National Vision Holdings, Inc.'s (EYE) pipeline across Phase 3. Its lead program is Inactivated SARS-CoV-2 Vaccine (Vero cell) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is National Vision Holdings, Inc.'s next FDA catalyst?→
National Vision Holdings, Inc.'s (EYE) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EYE biotech catalysts?→
Add EYE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow National Vision Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.